【-】2024年四季度制药生物工具风险投资趋势_9页_6mb

Pharma Biotech VC Ecosystem Summary

Overview: This report focuses on the venture capital (VC) ecosystem in pharma biotools, published on March 20, 2025. It serves as a VC-oriented replacement for the previous Pharmatech Report and will be succeeded by a PE-focused report in Q2 2025. Investment in pharma biotools mirrors broader biopharma cycles, with peaks in 2021 followed by a downturn in 2022-2023 and a resurgence in 2024.

VC Activity Trends: Post-2021, VC investment declined but rebounded in 2024. In Q4 2024, 59 deals were recorded with a total value of $0.7 billion, showing a 9.3% quarterly increase in deals but a 30.6% decrease in value from Q3 2024. Mature technologies attract less funding, while advanced segments like AI-driven drug discovery, synthetic biology, and lab automation receive robust VC support.

Investment and Market Dynamics: Key areas include AI-driven discovery, synthetic biology, and next-generation sequencing, drawing substantial investment despite some IPO/SPAC valuation pressures. A strategic shift occurs toward platform technologies with broad applications, such as those enabling multiple uses in drug development, rather than single-product companies. Diagnostics using multiomics approaches are gaining momentum, while lab automation and computational tools for drug discovery remain well-funded.

Deal Activity Details: Q4 2024 saw specific deals, such as Cradle (Generative AI) at $73 million and Codetta Bio (Multiomics) at $12.3 million. Over the trailing 12 months, deal counts and values vary by quarter, with Q4 2024 showing a moderate increase in transactions but a decline in total value.

Exit Activity: The report highlights exits since 2020, including IPOs and acquisitions of companies like Ginkgo Bioworks (Reverse merger) and Abcellera (Acquisition by Exact Sciences), reflecting successful transitions from VC to public or strategic buyers.

Quarterly Summary: For Q4 2023-Q4 2024, deal counts and values fluctuate: Q4 2023 had 57 deals ($0.6B), rising to 59 deals ($0.7B) in Q4 2024. The trend shows minor adjustments, with deal values generally reaching higher levels earlier, indicating resilience in the VC ecosystem for innovative pharma technologies.